Abstract-Statins have pleiotropic actions against the development of vascular remodeling and the incidence of ischemic stroke. Although previous studies have suggested that posttranslational modification of several proteins, such as Rho by mevalonate-derived isoprene groups, geranylgeranyl pyrophosphate or farnesyl pyrophosphate, underlie the pleiotropic effects of statins, the detailed mechanisms remain elusive. Recent growing evidence demonstrated that ClC-3 volume-regulated chloride channel plays an important role in cell proliferation, and the activity of this channel is increased in basilar smooth muscle cells from a hypertensive rat. We hypothesized that inhibition of volume-regulated chloride channel may contribute to the beneficial effects of statins on cerebrovascular remodeling during hypertension. Our study here demonstrated that simvastatin ameliorated hypertension-caused cerebrovascular remodeling. In rat basilar smooth muscle cells, simvastatin inhibited cell proliferation and activation of volume-regulated chloride channel, and these effects of simvastatin were abolished by pretreatment with mevalonate or geranylgeranyl pyrophosphate. In addition, Rho A inhibitor C3 exoenzyme and Rho kinase inhibitor Y-27632 both reduced cell proliferation and activation of volume-regulated chloride channel. Moreover, ClC-3 overexpression decreased the suppressive effect of simvastatin on cell proliferation and increased estimated IC 50 of simvastatin on endothelin 1-and hypo-osmolarityinduced cell proliferation from 3.40Ϯ0.08 and 3.50Ϯ0.10 mol/L to 5.30Ϯ0.70 and 5.60Ϯ0.70 mol/L, respectively (PϽ0.01; nϭ6). Furthermore, the expression of ClC-3 was increased in basilar artery during hypertension, and simvastatin normalized the upregulation of ClC-3. Our data suggested that simvastatin ameliorates cerebrovascular remodeling in the hypertensive rat through inhibition of vascular smooth muscle cell proliferation by suppression of volume-regulated chloride channel. (Hypertension. 2010;56:445-452.)
C erebral arterioles undergo remodeling of the vascular walls during chronic hypertension, which is caused by the coordination of vascular smooth muscle cell (SMC) proliferation and migration, endothelial cell dysfunction, inflammation, and fibrosis. [1] [2] [3] It has been generally accepted that vascular remodeling is an important determinant of increased risk of stroke that accompanies chronic hypertension. 4, 5 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are extensively used in clinic to treat hypercholesterolemia by inhibiting cholesterol biosynthesis. A number of large clinical trials and animal experiments have established that statins are available to reduce the mortality and morbidity of cardiovascular events, such as coronary artery disease and stroke. 6 -9 These beneficial effects of statins cannot be merely attributed to their lipid-lowering property. 8, 10 Recent growing evidence has demonstrated that statins have pleiotropic effects, including inhibition of vascular SMC proliferation, improvement of endothelial function, increase of NO availability, reduction of inflammatory response, and oxidative stress production. 8, 11, 12 It has been reported that these beneficial effects of statins are associated with the mevalonate (MVA)-derived isoprenoid intermediates, geranylgeranyl pyrophosphate (GGPP) and farnesyl pyrophosphate (FPP), which serve as lipid attachments for the posttranscriptional modification of several proteins, such as Ras, Rho, and Rac, to their active GTP-binding state. 10 -13 However, the detailed mechanisms by which statins exert these effects remain to be elucidated. It has been reported that statins could regulate the activities of a variety of ion channels, such as L-type calcium channel, 14 calcium-activated potassium chan-nel, 15 and nonselective cation channel, 16 in the vascular SMC and endothelial cell.
Volume-regulated chloride channel (VRCC) has been documented to play an important role in the regulation of cell volume, proliferation, differentiation, and apoptosis. [17] [18] [19] [20] [21] Although the molecular identity of VRCC is still under debate, our previous work demonstrated that ClC-3, a member of the voltage-gated ClC chloride channel family, is the key component of VRCC in vascular SMCs. 22 Moreover, our recent study found that the activity of VRCC is increased in hypertensive rat basilar SMCs (BASMCs), and its increment parallels the severity of the cerebrovascular remodeling, 23 suggesting that VRCC is involved in vascular remodeling process during chronic hypertension.
The aim of our present study, therefore, was to investigate the effects of simvastatin on the cerebrovascular remodeling in the 2-kidney 2-clip hypertension model. Furthermore, we evaluated the functional role of VRCC in the beneficial effects of simvastatin on rat cerebrovascular remodeling and BASMC proliferation.
Materials and Methods
An expanded Material and Methods is in the online Data Supplement, available at http://hyper.ahajournals.org.
All of the animal experimental procedures were performed in accordance with the policies of the Animal Care and Use Committee, Sun Yat-Sen University, and conformed to the "Guide for the Care and Use of Laboratory Animals" of the National Institute of Health in China. Four-to 5-week-old male Sprague-Dawley rats (body weight: 90 to 120 g) were anesthetized by injection of 10% chloral hydrate (3 mg/kg IP), and 2-kidney 2-clip renovascular hypertensive rats were operated as described previously. 23 Rats were divided into 3 groups, which were the sham, hypertension, and hypertensionϩ simvastatin groups. Simvastatin was dissolved in water and orally administered by gavage at a daily dose of 10 mg/kg after operation. Blood pressure (BP) was measured in conscious rats by tail-cuff plethysmography. Specimens of rat basilar arteries were cut for histochemistry, immunohistochemistry, and electron microscopy studies. Total proteins were extracted from the rat basilar arteries, and the expression of ClC-3 was measured with Western blot. Rat BASMCs were isolated and cultured from rat basilar arteries as described previously. 20 These cells were used to study the cell proliferation and to measure intracellular Cl Ϫ concentration ([Cl Ϫ ] i ) and transmembrane Cl Ϫ currents, as described previously. 22, 23 All of the data were expressed as meanϮSEM. Statistical analyses were performed using a Student t test or ANOVA. Values of PϽ0.05 were considered significant.
Results

Effects on BP
Consistent with our previous study in a 2-kidney 2-clip hypertensive rat model, 23 increased progressively after operation. Pretreatment with simvastatin mildly decreased the elevated BP from 8 weeks after operation. However, the BPs in the simvastatin-treated group were not significantly different from those in the hypertension group at 1 and 4 weeks after operation (Table) .
Simvastatin Prevented Hypertension-Induced Remodeling of Rat Basilar Artery
Cross-section histopathologic studies showed that the ␣-actin staining time-dependently increased in basilar arteries from hypertensive rats ( Figure S1 , available in the online Data Supplement at http://hyper.ahajournals.org). The lumen diameter decreased and the wall:lumen area ratio and the mean values of medial cross-sectional area increased in the hypertension group after 4 weeks postoperatively compared with those in the corresponding control groups. The wall diameter did not change until 8 weeks after operation. These changes indicated that the cerebral basilar artery from the hypertensive group underwent remodeling. Simvastatin treatment restored these phenotypes of hypertension-induced basilar artery remodeling from 4 weeks after operation (Figures 1  and S1 ). Electron microscopic observation demonstrated that the medial layer of the basilar artery in the hypertension group began to undergo remodeling from 4 weeks after operation, exhibiting migration and proliferation of SMCs, and increased accumulation of collagen fibers. These pathological changes were aggravated as hypertension was developing. From week 8, disarrangement of SMCs, migration of SMCs into the subendothelial region of intima, and accumulation of dense collagen fibers in the intercellular space were observed.
Necrosis of SMCs and endothelial cells, mitochondrial degeneration, and endoplasmic reticulum vacuolization were also shown in our studies. The above ultrastructural remodeling during hypertension was significantly attenuated by simvastatin ( Figure S2 ).
Simvastatin Inhibited BASMC Proliferation Induced by Endothelin 1 or Hypotonic Medium via the MVA Pathway
It has been established that SMC hyperplasia is one of the major causes of hypertension-induced vascular remodeling. 2, 24 So we examined the effect of simvastatin on BASMCs proliferation. Our results showed that simvastatin concentration-dependently inhibited BASMCs proliferation induced by 10 nmol/L of endothelin 1 (ET-1) and 25% hypotonic medium with estimated IC 50 values of 3.20Ϯ0.04 and 3.70Ϯ0.04 mol/L (nϭ6 from 6 independent experiments per group), respectively ( Figure S3 ).
To clarify whether simvastatin-elicited growth arrest was because of the inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase, we examined the effect of simvastatin on BASMC proliferation in the presence of MVA or its isoprenoid derivatives. MVA (100 mol/L) or GGPP (10 mol/L) treatment completely reversed the inhibitory effect of simvastatin on ET-1-or hypo-osmolarity-induced proliferation. FPP (10 mol/L) also remarkably attenuated the inhibitory effect of simvastatin on cell proliferation (Figures 2A and 2B and S4 ). These results indicated that the growth arrest elicited by simvastatin was related to the inhibition of the MVA pathway. To further demonstrate the role of geranylgeranylated proteins, such as Rho, in cell proliferation, we investigated the effects of RhoA and Rho kinase inhibitors on proliferation of BASMCs. Pretreatment with RhoA inhibitor clostridium botulinum C3 exoenzyme (0.25 g/mL) or Rho kinase inhibitor Y-27632 (10 mol/L) attenuated the proliferation of BASMCs induced by ET-1 or 25% hypotonic medium ( Figures 2C and 2D and S5 ).
Simvastatin Inhibited the Activity of VRCC by Interfering With the MVA Pathway
Because VRCC has been documented to play an important role in the regulation of cell proliferation, 17, 20, 25 we next examined the effect of simvastatin on the activity of VRCC in BASMCs. Pretreatment with simvastatin (2.5 to 10.0 mol/L) indeed inhibited the hypo-osmolarity-activated Cl Ϫ efflux and transmembrane Cl Ϫ current density in a concentration-dependent manner ( Figures S6 and S7) .
To determine whether the inhibitory effect of simvastatin on the activity of VRCC is mediated by the MVA pathway, 100 mol/L of MVA, 10 mol/L of GGPP, or 10 mol/L of FPP were added to the isotonic extracellular solution 5 minutes before simvastatin. As shown in Figure 3 , pretreatment of MVA or GGPP abolished the suppressive effects of simvastatin on hypo-osmolarity-activated Cl Ϫ efflux and Cl Ϫ current. FPP also significantly attenuated the inhibitory effect of simvastatin on the activity of VRCC. However, MVA, GGPP, or FPP alone had no effects on the activity of the channel ( Figure S8 ). These data indicated that GGPPdependent isoprenylation of some signaling molecules, such as Rho GTPase, mediates the effects of simvastatin.
RhoA/Rho Kinase Inhibitors Reduced the Activity of VRCC
To further determine whether the RhoA/Rho kinase pathway regulates the activity of the VRCC, we examined the effects of C3 exoenzyme and Y-27632 on hypotonicity-activated Cl Ϫ efflux and membrane Cl 
Simvastatin-Elicited Inhibition of Proliferation Positively Correlated With Its Suppressive Effect on Cl ؊ Efflux
Because simvastatin inhibited cell proliferation, as well as the activity of VRCC via the MVA pathway, we analyzed the correlation of the inhibitory effects of simvastatin on proliferation with those on hypotonicity-activated Cl Ϫ efflux by using the inhibition ratios of simvastatin at various concentrations. Figure 5 demonstrated that the inhibition ratio of simvastatin on ET-1-or hypo-osmolarity-induced BASMC proliferation positively correlated with the inhibition ratio of simvastatin on hypotonicity-activated Cl Ϫ efflux with correlation coefficients of 0.94 (nϭ30 cells from 6 independent experiments; PϽ0.001; Figure 5A ) or 0.84 (nϭ30 cells from 6 independent experiments; PϽ0.001; Figure 5B ), respectively, suggesting that VRCC may mediate the inhibitory effect of simvastatin on BASMC proliferation.
ClC-3 Overexpression Attenuated the Effect of Simvastatin on BASMC Proliferation
ClC-3 has been suggested to be the key component of VRCC in vascular SMCs. 22 Our results in the present study showed that ET-1 or hypotonic medium treatment increased the expression ClC-3 in BASMCs, and simvastatin reduced these effects ( Figure S9 ). To further investigate the functional role of ClC-3 in cell proliferation, we examined the effect of ClC-3 overexpression on proliferation by using ClC-3 cDNA transfection. Our results demonstrated that ClC-3 overexpression significantly increased cell proliferation in basal medium and enhanced proliferation induced by ET-1 or hypoosmolarity compared with that in the vector transfection group. Moreover, ClC-3 overexpression decreased the sup- pressive effect of simvastatin on proliferation induced by ET-1 or hypo-osmolarity and shifted the concentrationresponse curves of simvastatin to the right. ClC-3 overexpression increased the estimated IC 50 of simvastatin on ET-1-and hypo-osmolarity-induced proliferation from 3.40Ϯ0.08 and 3.50Ϯ0.10 mol/L to 5.30Ϯ0.70 and 5.60Ϯ0.70 mol/L, respectively (PϽ0.01; nϭ6; Figure 6 ). The data indicated that simvastatin reduces BASMC proliferation through, at least in part, inhibition of VRCC.
Simvastatin Inhibited the Increased Expression of ClC-3 in Rat Basilar Arteries During Hypertension
The immunohistochemical experiment showed that the fluorescent intensities of ClC-3 in basilar arteries were increased gradually with the development of cerebrovascular remodeling induced by hypertension. (Figure 7 ), and these results were further confirmed by Western blotting analysis ( Figure S10 ).
Discussion
Vascular remodeling, an adaptative response to increased BP, is considered as one of the major contributors to cardiovascular diseases, such as stroke. [1] [2] [3] 5, 26 Statins have been reported to be able to prevent the vascular remodeling of coronary artery, pulmonary artery, and carotid artery independent of their lipid-lowering effects. 7, 8, 10, 12, 13, 27 In this study, we found that the basilar artery exhibited a smaller lumen and external diameter and an increased media crosssectional area and media:lumen ratio in 2-kidney 2-clip hypertensive rats from 4 weeks after operation. These structural changes were consistent with our previous results in the same hypertensive model and the other laboratory's findings in spontaneously hypertensive rats. 3, 23, 28 Simvastatin treatment prevented the alterations of the cerebrovascular structure from 4 weeks after operation. Moreover, simvastatin decreased BP at 8 and 12 weeks postoperatively by Ϸ30 and 50 mm Hg, respectively. Our findings that simavastin reduced BP were in good agreement with several recent clinical trials and experimental animal studies that demonstrated that statins exhibited a modest BP-lowering effect in hypertensive subjects. 29 Although the BPs in the simvastatin-treated group were not significantly different from those in the hypertension group at 1 and 4 weeks after operation, our results cannot exclude the possibility that the BP-lowering effect of simvastatin may contribute to its beneficial effects on cerebrovascular remodeling. It is well established that abnormal SMC proliferation contributes to hypertension-induced vascular remodeling. 24, 30 Statins have been demonstrated to inhibit SMC proliferation in vitro and in vivo independent of lipid-lowing effects and, thus, to ameliorate vascular proliferative disease. 6,10 -12,27,31,32 The pleiotropic effects of statins on proliferation and migration of SMC are considered to be derived from inhibition of isoprenoid intermediates, which serve as the lipid attachments for the posttranslational modification of a variety of proteins, such as those in the Rho and Rac GTPase family. 6, 10, 11, 27 In the present study, simvastatin inhibited the cultured rat BASMC proliferation induced by hypotonic medium and ET-1. MVA and GGPP preincubation abolished the inhibitory effect of simvastatin on cell proliferation. These data demonstrated that simvastatin inhibited BASMC proliferation via modifying Rho geranylgeranylation. Although several molecules, such as p21 kip1 and extracellular regulated kinase, 32, 33 have been reported to mediate the functional roles of Rho signaling in the regulation of cell proliferation, the downstream effectors of active Rho remain elusive.
During the early phase of cell proliferation, cells undergo swelling because of water influx, which accompanies the uptake of nutrients necessary for cell metabolism. An increase in cell volume will initiate the regulatory volume decrease process through activation of ion (K and Cl) channels and transporters, which activates K and Cl efflux to normalize the cell size. 19, 34 VRCC contributes to the regulatory volume decrease process; therefore, this channel has been suggested to play a critical role in the regulation of cell proliferation. Our previous studies have demonstrated that pharmacological inhibition of VRCC or knockdown of ClC-3 reduced rat aortic SMC proliferation induced by ET-1. 25, 35, 36 In addition, our recent work in rat BASMCs demonstrated that ClC-3 silence inhibited cell proliferation and cell cycle progression. 20 Our results in this study showed that hypoosmolarity-induced cell swelling stimulated rat BASMC proliferation, further supporting the functional role of VRCC in the regulation of cell growth.
The Rho-Rho kinase pathway has been documented to be involved in the regulation of volume-regulated chloride current in NIH3T3 mouse fibroblasts and pulmonary artery endothelial cells. 37, 38 Our data in this study showed that the Rho-Rho kinase pathway is necessary for the activation of VRCC in rat BASMCs because the Rho and Rho kinase inhibitors blocked hypo-osmolarity-induced chloride efflux and transmembrane chloride current. Because statins modify the activity of Rho GTPase, we next tested the effect of simvastatin on the activation of VRCC. We found that simvastatin inhibited hypotonicity-activated chloride movement and volume-regulated chloride current in a concentration-dependent manner. Similar results were also observed after lovastatin treatment (data not shown). The inhibitory effect of simvastatin on activation of VRCC was abolished by MVA and GGPP pretreatment, suggesting that simvastatin inhibited VRCC via modifying Rho activity.
Vascular SMC volume increase has been suggested to be the primary change responsible for the hypertrophy of mesenteric arterial media in spontaneously hypertensive rats. 36 In BASMCs, we found that the cell volume was increased during the development of hypertension in hypertensive rats. 23 In addition, the activity of VRCC is also increased during hypertension, and its increment parallels the severity of the vascular remodeling, 23 suggesting that VRCC may be associated with the abnormal vascular SMC proliferation and vascular remodeling during hypertension. Our present work demonstrated that ET-1 and hypotonic medium increased cell proliferation, as well as ClC-3 expression, and simvastatin treatment inhibited the upregulation of ClC-3 caused by ET-1 and hypo-osmolarity. In addition, the expression of ClC-3 in basilar arteries was increased gradually with the development of cerebrovascular remodeling induced by hypertension. Simvastatin treatment normalized the structural alterations, as well as ClC-3 expression, in the basilar artery of hypertensive rats. Moreover, ClC-3 overexpression in BASMCs decreased the inhibitory effect of simvastatin on cell proliferation. These findings indicated that inhibition of VRCC underlies the beneficial effects of simvastatin on vascular remodeling during hypertension.
Perspectives
VRCC has been suggested to play an important role in the regulation of cell volume, proliferation, and apoptosis. The present study provides new mechanistic insights that inhibition of VRCC contributes to the beneficial effects of simvastatin on cerebrovascular remolding. The data suggest that VRCC is a potential target for the prevention of cerebrovascular remodeling and stroke. Future studies are needed to investigate the functional role, as well as the mechanisms, of VRCC in the development of vascular remolding during hypertension in ClCn-3 transgenic and knockout mice.
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ONLINE SUPPLEMENT Materials and Methods
Cell culture medium, fetal calf serum and BrdU Assay Kit were provided by Invitrogen. Mevalonate, geranylgeranylpyrophosphate (GGPP), farnesylpyrophosphate (FPP), Clostridium botulinum C3 exoenzyme, Y-27632 ( (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) ), α-actin monoclonal antibody was purchased from Sigma. 6-Methoxy-N-ethylquinolinium iodide (MEQ) were from Molecular Probes. ClC-3 rabbit polyclonal antibody was provided by Alomon Labs (Jerusalem, Israel). gpClC-3/pcDNA3.1 was kindly provided by Dr. J.R. Hume (University of Nevada School of Medicine, Reno, Nevada, USA).
Simvastatin was kindly provided by Merck Sharp & Dohme (Hangzhou, China) and was prepared for in vitro use as described previously 1 . Briefly, the inactive lactone was converted into the active form by dissolving 20 mg lactone in 0.5 ml 100% ethanol, after adding 0.75 µl 0.1 mol/L NaOH , the solution was heated at 50℃ for 2 h. The pH of the solution was adjusted to 7.2 with 0.1 mol/L HCl and then simvastatin was diluted to 5 mmol/L stock solution with PBS. Animals were supplied by the Experimental Animal Center of Sun Yat-Sen University in Guangzhou, China. All experimental procedures were performed in accordance with the policies of the Sun Yat-Sen University Animal Care and Use Committee and comformed to the "Guide for the Care and Use of Laboratory Animals" of the National Institute of Health in China. Animal model and blood pressure measurement 2-kidney, 2 clip (2k2c) renovascular stroke-prone hypertensive rats were operated as previously described 2, 3 . Briefly, healthy male Sprague-Dawley rats (90-120g) were anaesthetized by injection of 10% chloral hydrate (3 mg/kg, i.p.), and ring-shaped silver clips with the internal diameter of 0.3 mm were placed around both right and left renal arteries. The sham-operated rats underwent the same surgical procedure except for the placement of silver clips and served as control. Systolic blood pressure (SBP) was measured in conscious rats by tail-cuff plethysmography (powerlab 4/30, ADInstruments, Australia). Simvastatin (Merk Sharp & Dohme Ltd. Northumberland. UK) was dissolved in water and orally administered by gavage at a daily dose of 10 mg/kg after operation. All rats were maintained in pathogen-free facilities with a 12-hour light/dark cycle. Immunohistochemistry Rats were anesthetized with 10% chloraldurat and were perfused intracardiacly with 0.1 mol/L phosphate buffer containing heparin (100 U/kg) and nitroglycerol (0.3 μg/kg), followed by 4ºC fixative solution containing 4% freshly depolymerized paraformaldehyde in 0.1 mol/L phosphate buffer for 15 minutes, the pressure was controlled ≈100mmHg. The rat brain was carefully removed and sections (8 µm) were prepared from freshly frozen rat basilar arteries as previously described 3, 4 . Randomly selected 3 sections in each group were pretreated with the solution of 3% hydrogen peroxide and methanol at the ratio of 1:50 for 30min at room temperature, and then blocked with 5% bovine serum albumin in PBS for 30min. Then the sections were exposed to α-actin monoclonal antibody (Sigma; dilution 1:400) or ClC-3 rabbit polyclonal antibody (Alomone Labs; dilution 1:100) at 4°C overnight and then were treated with goat FITC-conjugated secondary antibody (Cell Signaling Technology; dilution 1:400) or Alexa Fluor® 488 goat anti-rabbit IgG (Cell Signaling Technology; dilution 1:400 )at room temperature for 30min. The quantification of α-SM-actin staining was analyzed using confocal system (OLYMPUS, FV500-IX 81, magnification 400 ) and Image-Pro Plus 5.0. For each tested group at each time point, 6 rat brains were taken for the experiment, respectively.
Electron microscopy
Rats were anesthetized with 10% chloraldurat and were perfused intracardiacly with 0.1 mol/L phosphate buffer containing heparin (100 U/kg) and nitroglycerol (0.3 μg/kg), followed by 4ºC fixative solution containing 4% paraformaldehyde, 0.25% glutaral, 15% saturated trinitrophenol in 0.1 mol/L phosphate buffer for 15 minutes, the pressure was controlled ≈100mmHg. The brain tissue containing the basilar artery at midpoint were removed and were cut into blocks of 1mm×1mm×3mm，and then immersed into fixative solution overnight at 4ºC. The tissue blocks were postfixed in 2% osmic acid for 2h, dehydrated via graded alcohols and embedded in Epon 812. Ultrathin sections with thickness of 80~100nm were prepared and stained with uranyl acetate and lead citrate before they were viewed with a transmission H-600 electron microscope(Hitachi, Japan).
Cell culture
Rat basilar smooth muscle cells (BASMCs) were isolated and cultured from rat basilar arteries using explant method as previously described [5] [6] [7] [8] . Briefly, male Sprague-Dawley rats (150~180g) were anaesthetized with ether and decapitated. The basilar arteries were harvested immediately and immersed in Kreb's solution containing (mmol/L): NaCl 137, KCl 5.4, CaCl 2 2.0, MgCl 2 1.1, NaH 2 PO 4 0.4, Glucose 5.6, NaHCO 3 11.9, 10 5 U/L penicillin and 100 mg/L streptomycin. After fat and connective tissue was cleaned, the basilar arteries were cut into small pieces about 0.5 mm long and the vessel segments were placed on the surface of the culture dish. The dish was then incubated in Dulbecco's Modified Essential Medium (DMEM)/F-12 supplemented with 20% fetal calf serum (FCS) at 37°C, 5% CO 2 . 3 days later, the floating tissues were discarded and fresh DMEM/F-12 containing 20% FCS was added. The cells will migrate from the attached vascular specimens about 7-10 days. After reaching 70% confluence, cells were then subcultured with 0.25% trypsin with 0.02% EDTA. Passage 8 to 12 of BASMCs at 70% to 90% confluence were growth-arrested by incubation in DMEM/F12 with 0.5% FCS for 24 hours before experiments. BASMCs were identified by positive immunocytochemical staining with a monoclonal antibody against smooth muscle α-actin and by the characteristic "hill and valley" growth pattern.
Proliferation assays
Cell proliferation was assessed by cell counts and 5-bromo-2'-deoxyuridine (BrdU) incorporation as we reported previously 6, 9, 10 . For the cell counts, BASMCs were trypsinized and plated into 6-well culture plates at a density of 5×10 5 cells/well in DMEM/F-12 supplemented with 10% FCS. After 24 hours, cells were rendered quiescent in 0.5% FCS for 24 hours before addition of fresh growth medium containing the appropriate supplements. Cell number was determined in triplicate using a hemocytometer. The DNA synthesis was assessed by BrdU incorporation. After starvation for 24 hours, cells were treated with the same supplements used in the cell count experiment before adding 10 mmol/L BrdU to the medium. 18 hours later, cells were fixed and treated with anti-BrdU primary antibody for 1 h at room temperature. After incubation with horseradish peroxidase-conjugated goat anti-IgG for 30 min, 100 mmol/L 3,3′,5,5′-tetramethylbensidine was then added as the substrate for horseradish peroxidase. The incorporation was measured at 450 and 540nm on an Elisa microplate reader (BIO-TEK synergy HT, American).
The inhibition ratios of simvastatin (sim, 2.5-10 μmol/L) on ET-1 or 25% hypotonic medium (hypo) induced proliferation were calculated as follows: (OD ET-1 -OD ET-1+sim )/ (OD ET-1 -OD control )×100% or (OD hypo -OD hypo+sim )/ (OD hypo -OD control )×100% gpClC-3 cDNA transfection gpClC-3/pcDNA3.1 plasmid was transfected as previously decribed 11 .
Briefly, BASMCs were plated on 24-well plate at a density of 1-1. . Briefly, MEQ was first reduced to a cell-permeable form, 6-methoxy-N-ethyl-1,2-dihydroquinoline (diH-MEQ). Then Cells were incubated with 100-150 μmol/L diH-MEQ in a Ringer's buffer solution containing (mmol/L) :119 NaCl, 2. Recordings were started 5 min after the establishment of the whole-cell configuration to allow the equilibration of the pipette solution with cell interior. The currents were elicited with voltage steps from -100mV to +120mV in +20mV increament for 400ms with an interval of 5s from a holding potential of -40mV. Currents were sampled at 5 kHz using pCLAMP8.0 software (Axon Instruments) and filtered at 2 kHz. To minimize the changes of liquid junction potentials, a 3 mM KCl-agar salt bridge between the bath and the Ag-AgCl reference electrode was used. All experiments were performed at room temperature (25℃).
Western blot analysis
Total proteins were prepared from the cultured BASMCs or pooled basilar arteries from sham group, hypertensive rats with or without simvastatin treatment (4 basilar arteries from each group were used as 1 sample), and western blotting was performed as previously described 10, 11 . Briefly, the protein content was quantified with Coomassie Brilliant Blue. Aliquots containing 30 µg of proteins from each group were subjected to SDS-PAGE and were then transferred to nitrocellulose membranes (Schleicher & Schuell). After incubation with the blocking solution at room temperature for 1 hour, the membranes were incubated with a rabbit antibody against ClC-3 diluted 1:400 for 1 hour at room temperature, and then incubated with a horseradish Fig S1   Figure S1 . Simvastatin ameliorated the morphological changes of rat cerebral basilar artery during hypertension. Vascular media smooth muscle was specific stained as brown with α-smooth muscle actin antibody. Representative pictures were taken from the rat basilar arteries of control (Con), hypertensive rats without (Htn) or with simvastatin (Sim) treatment at 1w, 4w, 8w and 12w after operation, respectively (×200). At each time point, 6 rats were studied in Figure S10 . Simvastatin normalized the increased expression of ClC-3 in rat basilar artery during hypertension. Basilar arteries were collected from control, hypertensive rats with or without simvastatin treatment. Tissue protein was prepared and subjected to SDS-PAGE. A. Western blot analysis showed that, from 4 week after operation, the ClC-3 protein expression in basilar artery from hypertensive rat was increased compared with the corresponding sham rat (*p<0.01 vs corresponding sham group, n=4 from 12 rats per group). B. Simvastatin attenuated the increased expression of ClC-3 in hypertensive rats at 12 weeks after operation (*p<0.01 vs sham group, #p<0.01 vs hypertension group, n=4 from 12 rats per group).
